Immunai CEO and leadership

Luis Voloch is the Chief Technology Officer and Co-Founder at Immunai, where he and the Immunai team are helping bring transformational change to immunology, cancer, science, and beyond by leveraging cutting edge AI, software, immunology, computational biology, and genomics technologies to fully map and reprogram the immune system.

Before co-founding Immunai, Luis served as Head of Data Science and Machine Learning and worked on a variety of Machine Learning efforts at Palantir and other companies, where he has worked on and led various AI, genomics, and software efforts.

Luis studied at the Massachusetts Institute of Technology for his BS in Mathematics and Computer Science and his Masters in Electrical Engineering and Computer Science, and won the prestigious Best Thesis award among all PhD-track students at the Massachusetts Institute of Technology’s Electrical Engineering and Computer Science department before leaving to industry.

Jacques Banchereau is an internationally prominent French American immunologist and molecular biologist. As of 2018, he is professor and director of immunological sciences at the Jackson Laboratory for Genomic Medicine. He was also the former chief science officer, senior vice president, and DTA (Discovery and Translational Area) head of inflammation & virology at Hoffman-La Roche.[l] He is best known for his extensive research on dendritic cellsC2] with Nobel Laureate Ralph M. Steinman. He is the fifth most cited immunologist ranked by Times Higher Education's report.

Prior to iSkoot Mark was an Entrepreneur in Residence at Charles River Ventures, and prior to that served as the EVP at Silicon Valley-based loopt, Inc., a ground-breaking social mapping startup backed by Sequoia Capital and New Enterprise Associates. Before joining loopt, Jacobstein was the founding President for Digital Chocolate, one of the world's largest publishers of mobile games, which raised more than $20M in venture capital from Sequoia Capital, KPCB, and Sutter Hill. Mark was also the CEO and founder of Small World Sports, the world's first online fantasy sports business, where he raised more than $20M from Flatiron Ventures, SCP, CCP and NBC before selling the business to Paul Allen's The Sporting News. In addition, Jacobstein co-founded Small World Software, an Internet technology consultancy, which he sold to iXL in 1998. He then served as the SVP of sales and business development for iXL's New York office before its 1999 IPO. Jacobstein studied Computer Science at Harvard University and began his career as a software developer at Bloomberg L.P.

Luis Voloch is the Chief Technology Officer and Co-Founder at Immunai, where he and the Immunai team are helping bring transformational change to immunology, cancer, science, and beyond by leveraging cutting edge AI, software, immunology, computational biology, and genomics technologies to fully map and reprogram the immune system.

Before co-founding Immunai, Luis served as Head of Data Science and Machine Learning and worked on a variety of Machine Learning efforts at Palantir and other companies, where he has worked on and led various AI, genomics, and software efforts.

Luis studied at the Massachusetts Institute of Technology for his BS in Mathematics and Computer Science and his Masters in Electrical Engineering and Computer Science, and won the prestigious Best Thesis award among all PhD-track students at the Massachusetts Institute of Technology’s Electrical Engineering and Computer Science department before leaving to industry.